Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) saw a large growth in short interest during the month of June. As of June 15th, there was short interest totalling 9,450,000 shares, a growth of 7.6% from the May 31st total of 8,780,000 shares. Based on an average trading volume of 3,190,000 shares, the short-interest ratio is presently 3.0 days.
Insider Activity
In other Exact Sciences news, CEO Kevin T. Conroy sold 1,155 shares of the business’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $60.15, for a total transaction of $69,473.25. Following the sale, the chief executive officer now owns 1,156,191 shares in the company, valued at approximately $69,544,888.65. The transaction was disclosed in a filing with the SEC, which is available through this link. In the last 90 days, insiders sold 1,498 shares of company stock worth $90,105. Insiders own 1.36% of the company’s stock.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the company. Wolff Wiese Magana LLC raised its holdings in shares of Exact Sciences by 459.5% in the fourth quarter. Wolff Wiese Magana LLC now owns 414 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 340 shares during the last quarter. Benjamin F. Edwards & Company Inc. raised its holdings in Exact Sciences by 65.6% during the first quarter. Benjamin F. Edwards & Company Inc. now owns 452 shares of the medical research company’s stock worth $31,000 after acquiring an additional 179 shares in the last quarter. Able Wealth Management LLC bought a new stake in Exact Sciences during the fourth quarter worth about $45,000. EverSource Wealth Advisors LLC boosted its position in Exact Sciences by 92.4% during the first quarter. EverSource Wealth Advisors LLC now owns 708 shares of the medical research company’s stock valued at $49,000 after purchasing an additional 340 shares during the last quarter. Finally, Fortitude Family Office LLC bought a new position in Exact Sciences in the first quarter valued at approximately $55,000. Institutional investors own 88.82% of the company’s stock.
Analyst Upgrades and Downgrades
Get Our Latest Stock Report on EXAS
Exact Sciences Price Performance
Shares of NASDAQ:EXAS traded up $0.74 during trading on Tuesday, reaching $43.17. The stock had a trading volume of 1,872,740 shares, compared to its average volume of 2,664,259. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.64 and a quick ratio of 1.45. The stock has a market capitalization of $7.97 billion, a PE ratio of -32.70 and a beta of 1.22. The business’s 50-day moving average price is $49.60 and its 200 day moving average price is $59.82. Exact Sciences has a 52 week low of $40.62 and a 52 week high of $100.77.
Exact Sciences (NASDAQ:EXAS – Get Free Report) last posted its quarterly earnings data on Wednesday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, hitting the consensus estimate of ($0.50). The firm had revenue of $637.52 million during the quarter, compared to analysts’ expectations of $624.95 million. Exact Sciences had a negative net margin of 9.48% and a negative return on equity of 7.12%. As a group, equities analysts predict that Exact Sciences will post -1.15 earnings per share for the current year.
About Exact Sciences
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
Featured Articles
- Five stocks we like better than Exact Sciences
- 3 Healthcare Dividend Stocks to Buy
- RXO Shares Surge Following New Acquisition Deal
- What is the Shanghai Stock Exchange Composite Index?
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.